A federal consultative group voted Thursday to loosen rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is advisory only. The FDA has given no word on whether it will adopt the suggestion. The move came after weeks of open hearings. Wellness backers pressed strongly for wider access. RFK Jr. was among them. Critics say these compounds have no solid safety track record or help for most uses. The call could shift how the agency handles a part of the wellness market that is surging ahead. Watchers are waiting to see if the agency adopts the plan. A representative for the regulator offered no fixed date for a next move. Backers argue the change would open up access to substances some say help. Health groups warn that looser rules could invite misuse across a fast-moving market. The panel vote only plants the seed for a shift, and the final decision rests with the regulator.